Name：XIA Guimin

Department：Pharmaceutics Department, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, PR China.

Tel: (8610)63150697

Email: xiaguimin@imb.pumc.edu.cn

Education & Research Experience

2021/09 - Now Research Professor, Pharmaceutics Department, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College.

2004/04 – 2021/08 Senior Engineer and Associate Professor, Pharmaceutics Department, Institute of Medicinal Biotechnology, Chinese Academy of Medical Science and Peking Union Medical College.

1988/07 - 2004/04 Senior Engineer, Pharmaceutics Department, Institute of Antibiotics, North China Pharmaceutical Group Co. Ltd.

1984/09 - 1988/07 Bachelor of Science in Pharmaceutics, Shenyang Pharmaceutical University.

Research Field

Nano delivery system and sustained and controlled-release preparations.

Research Interests：

Xia Guimin has been engaged in the pharmaceutics, including tumor-targeting nano-delivery system, co-delivery system for siRNA/miRNA and small molecule drugs, targeted nano biological materials and sustained and controlled preparations of active ingredients from drug or natural products. The projects she has been in charge of or mainly participated in include National Key Research and Development Program, National Natural Science Foundation of China, National High Technology Research and Development Program of China (863 Program), National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Eleventh/Twelfth/Thirteenth Five-year Plan Period, Scientific and Technological Innovation Project and Beijing Science and Technology Plan (Key Project), etc. What’s more, she has hosted several new drug research and development projects, involving anti-HIV drug, anti-cancer drug and new type of immunosuppressant, among which number of drugs have gained the permission of CFDA and been used clinically. She has published more than 40 research papers in Chinese and international journals and been awarded 19 Chinese invention patents.

Selected Publications

[1] A novel 5-Fluorouracil carbonate-loaded liposome: preparation, in vitro and in vivo evaluation as an antitumor agent, Molecular Pharmaceutics, 2022 (19):2061-2076, 2022

[2] Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle, European Journal of Pharmaceutical Sciences, 167: e106000, 2021.

[3] Antisense microRNA185 loaded liposome for efficient inhibition of the hepatic endogenous microRNA185 level, European Journal of Pharmaceutical Sciences, 161: e105803, 2021.

[4]. Evaluation of antitumor efficacy of folate-poly(2-ethyl-2-oxazoline)-distearoyl phosphatidyl ethanolamine based liposome, Pharmaceutical Development and Technology, 26(1):110-118, 2021.

[5] Endocytosis and Organelle targeting of nanomedicines in cancer therapy. International journal of nanomedicine.15: 9447-9467, 2020.

Awards and Honors  

2019 National Prize for Progress in Science and Technology.

2002 Outstanding Mid-Aged Expert of Hebei Province.